Pharmaceutical company Johnson & Johnson has announced that its Covid-19 vaccine is effective against the Delta variant, which was first identified in India back in April. The company stated that the vaccine’s immune response lasts eight months.
Research revealed that the antibodies and immune system cells in the blood of eight vaccinated people neutralised the Delta strain. Similar results were found in a second study of 20 people at Boston’s Beth Israel Medical Centre.
Johnson & Johnson’s chief scientific officer Paul Stoffels stated, “We believe that our vaccine offers durable protection against Covid-19 and elicits neutralising activity against the Delta variant,”.
Head of Janssen Research and Development at Johnson & Johnson Mathai Mammen stated that the eight months of research shows that the vaccine generates a strong neutralising antibody response that improves over time.
The data has been sent to bioRxiv, who will make the findings available to the scientific community and receive feedback on draft manuscripts before they are submitted to journals.
The National Public Health Emergency Team (NPHET) stated that approximately 70% of Covid-19 cases in Ireland are down to the Delta variant, with the European Centre for Disease Control (ECDC) stating that it will account for 90% of new cases in the EU by the end of August.